CDT Equity (CDT) Stock Price, News & Analysis

Company Overview

Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.

Key Stats

• Today's Range: $1.52 to $1.68
• 50-Day Range: $1.52 to $2.88
• 52-Week Range: $1.47 to $274.80
• Volume: 72,636 shs
• Average Volume: 85,931 shs
• Market Capitalization: $4.92 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CDT Equity Stock Analysis - MarketRank™

CDT Equity scored higher than 1% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for CDT Equity.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of CDT Equity is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of CDT Equity is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

CDT Equity has a P/B Ratio of 1.39. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.59% of the float of CDT Equity has been sold short.

Short Interest Ratio / Days to Cover

CDT Equity has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in CDT Equity has recently increased by 77.16%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

CDT Equity does not currently pay a dividend.

Dividend Growth

CDT Equity does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.59% of the float of CDT Equity has been sold short.

Short Interest Ratio / Days to Cover

CDT Equity has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in CDT Equity has recently increased by 77.16%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 1 people have searched for CDT on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, CDT Equity insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 7.72% of the stock of CDT Equity is held by insiders.

Percentage Held by Institutions

Only 3.29% of the stock of CDT Equity is held by institutions.

CDT Stock Analysis - Frequently Asked Questions

How have CDT shares performed this year?

CDT Equity's stock was trading at $102.90 at the start of the year. Since then, CDT stock has decreased by 98.4% and is now trading at $1.68.

How were CDT Equity's earnings last quarter?

CDT Equity Inc. (NASDAQ:CDT) released its quarterly earnings results on Thursday, August, 14th. The company reported ($5.46) EPS for the quarter.

When did CDT Equity's stock split?

CDT Equity shares reverse split on Tuesday, May 20th 2025.The 1-15 reverse split was announced on Friday, May 16th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 19th 2025. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

How do I buy shares of CDT Equity?

Shares of CDT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of CDT Equity own?

Based on aggregate information from My MarketBeat watchlists, some other companies that CDT Equity investors own include BIOLASE (BIOL), Dare Bioscience (DARE), Faraday Future Intelligent Electric (FFIE), AMC Entertainment (AMC), Cara Therapeutics (CARA), Canoo (GOEV) and Jiuzi (JZXN).

Company Calendar

• Last Earnings: 8/14/2025
• Today: 8/23/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CDT
• Previous Symbol: NASDAQ:CDT
• CIK: 1896212
• Web: www.conduitpharma.com
• Phone: 760-471-8536
• Fax: N/A
• Employees: 3
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($435.00)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$17.80 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -350.23%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.45
• Quick Ratio: 1.31

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.21 per share
• Price / Book: 1.39

Miscellaneous

• Outstanding Shares: 2,930,000
• Free Float: 2,700,000
• Market Cap: $4.92 million
• Optionable: Not Optionable
• Beta: 1.93